Johnson & Johnson (NYSE:JNJ) updated its FY 2019 earnings guidance on Tuesday. The company provided EPS guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.60. The company issued revenue guidance of $80.8-81.6 billion, compared to the consensus revenue estimate of $81.22 billion.Johnson & Johnson also updated its FY19 guidance to $8.53-8.63 EPS.

A number of equities analysts recently commented on the company. Wells Fargo & Co increased their price target on Wingstop from $76.00 to $84.00 and gave the company an outperform rating in a research note on Monday, May 6th. BMO Capital Markets assumed coverage on Yelp in a research note on Wednesday, April 17th. They issued an outperform rating for the company. Zacks Investment Research raised Jack Henry & Associates from a sell rating to a hold rating in a research note on Wednesday, March 27th. Credit Suisse Group set a $92.00 price objective on Ashland Global and gave the company a buy rating in a research note on Friday, July 12th. Finally, Goldman Sachs Group set a $27.00 price objective on Melco Resorts & Entertainment and gave the company a buy rating in a research note on Tuesday, May 28th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of Buy and an average target price of $150.44.

Shares of JNJ stock opened at $132.50 on Wednesday. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.44 and a quick ratio of 1.13. The company has a market cap of $357.66 billion, a price-to-earnings ratio of 16.20, a P/E/G ratio of 2.33 and a beta of 0.70. The business’s 50 day simple moving average is $138.45.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The firm had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same period last year, the company earned $2.10 EPS. Johnson & Johnson’s quarterly revenue was down 1.3% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.87%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 46.45%.

In other news, Director Marillyn A. Hewson acquired 3,000 shares of Johnson & Johnson stock in a transaction on Tuesday, June 11th. The shares were bought at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $419,040. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.23% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Why does the United States have a lingering trade deficit?

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.